共 50 条
- [31] Interim Report of A Phase 2 Clinical Trial of Lenalidomide for T-Cell Non-Hodgkin LymphomaCANCER, 2010, 116 (19) : 4541 - 4548Dueck, GregChua, NeilPrasad, AngeliFinch, DaygenStewart, DougWhite, Darrellvan der Jagt, RichardJohnston, JamesBelch, AndrewReiman, Tony
- [32] Phase II Clinical Trial of Denileukin Diftitox In Combination with Rituximab In Previously Untreated Follicular B-Cell Non-Hodgkin's LymphomaBLOOD, 2010, 116 (21) : 1178 - 1179Ansell, Stephen M.Tang, HuiNowakowski, Grzegorz S.Nikcevich, DanielNelson, Garth D.Erlichman, CharlesWitzig, Thomas E.
- [33] A Phase II Trial of Bortezomib Added to Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients with Previously Untreated Indolent Non-Hodgkin's LymphomaBLOOD, 2014, 124 (21)Cohen, Jonathon B.Switchenko, JeffreyKoff, Jean L.Sinha, RajniKaufman, Jonathan L.Khoury, H. JeanBumpers, Nassoma K.Colbert, AmandaHutchison-Rzepka, Amanda A.Nastoupil, Loretta J.Heffner, Leonard T.Langston, AmeliaLechowicz, Mary JoLonial, SagarFlowers, Christopher R.
- [34] A multicentre phase II study of vorinostat in patients with relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphomaBRITISH JOURNAL OF HAEMATOLOGY, 2014, 165 (06) : 768 - 776Ogura, MichinoriAndo, KiyoshiSuzuki, TatsuyaIshizawa, KenichiOh, Sung YongItoh, KuniakiYamamoto, KazuhitoAu, Wing YanTien, Hwei-FangMatsuno, YoshihiroTerauchi, TakashiYamamoto, KeikoMori, MasahikoTanaka, YoshinobuShimamoto, TakashiTobinai, KenseiKim, Won Seog
- [35] A Phase I Trial of Ibrutinib Plus Palbociclib in Patients with Previously Treated Mantle Cell LymphomaBLOOD, 2016, 128 (22)Martin, PeterBlum, KristieBartlett, Nancy L.Park, Steven I.Maddocks, Kami J.Ruan, JiaDi Liberto, MaurizioHuang, XiangaoInghirami, GiorgioHarris, PamelaChen-Kiang, SelinaLeonard, John P.
- [36] Phase II results of bendamustine in combination with rituximab in relapsed indolent and mantle-cell non-hodgkin's lymphomaCANCER INVESTIGATION, 2007, 25 : 35 - 36van der Jagt, Richard H.Cohen, PhilipCheson, BruceTulpule, AnilHerst, Jordan A.Lemieux, BernardSchwartzberg, Lee S.Robinson, K. SueOliver, Jennifer W.Williams, Michael E.
- [37] Phase II study of rituximab in combination with CHOP chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphomaJOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (02) : 389 - 397Vose, JMLink, BKGrossbard, MLCzuczman, MGrillo-Lopez, AGilman, PLowe, AKunkel, LAFisher, RI
- [38] Interim analysis of a phase II study of denileukin diftitox (Ontak) for relapsed/refractory T-cell non-Hodgkin's lymphoma.BLOOD, 2004, 104 (11) : 722A - 722ADang, NHPro, BHagemeister, FBJones, DSamuels, BRodriguez, MAGoy, ARomaguera, JEWalker, PLKwak, LFayad, L
- [39] Phase II clinical trial of interleukin-12 in patients with relapsed and refractory non-Hodgkin's lymphoma and Hodgkin's diseaseCLINICAL CANCER RESEARCH, 2004, 10 (16) : 5432 - 5438Younes, APro, BRobertson, MJFlinn, IWRomaguera, JEHagemeister, FDang, NHFiumara, PLoyer, EMCabanillas, FFMcLaughlin, PWRodriguez, MASamaniego, F
- [40] Excessive neurotoxicity in a phase II trial of combined bortezomib and rituximab in patients with relapsed/refractory mantle cell (MCL) and follicular (FL) non-Hodgkin's lymphoma.BLOOD, 2006, 108 (11) : 784A - 784ABlum, Kristie A.Lucas, Margaret S.Johnston, Jeffrey S.Dalton, JamesYoung, DonnBaiocchi, Robert A.Lin, Thomas S.Porcu, PierluigiByrd, John C.